KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Invested Capital (2016 - 2025)

Gilead Sciences' Invested Capital history spans 17 years, with the latest figure at $47.6 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 3.29% year-over-year to $47.6 billion; the TTM value through Dec 2025 reached $47.6 billion, up 3.29%, while the annual FY2025 figure was $47.6 billion, 3.29% up from the prior year.
  • Invested Capital reached $47.6 billion in Q4 2025 per GILD's latest filing, up from $46.4 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $49.9 billion in Q2 2021 to a low of $41.5 billion in Q2 2024.
  • Average Invested Capital over 5 years is $46.2 billion, with a median of $46.4 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: soared 162.63% in 2021, then fell 11.83% in 2024.
  • A 5-year view of Invested Capital shows it stood at $47.8 billion in 2021, then decreased by 2.77% to $46.4 billion in 2022, then increased by 2.8% to $47.7 billion in 2023, then fell by 3.55% to $46.0 billion in 2024, then increased by 3.29% to $47.6 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Invested Capital are $47.6 billion (Q4 2025), $46.4 billion (Q3 2025), and $44.5 billion (Q2 2025).